Core Viewpoint - The stock of HAPO Pharmaceuticals-B (02142) has increased by over 3%, currently trading at 12.67 HKD with a transaction volume of 30.48 million HKD, following the announcement of a successful project approval related to pancreatic cancer research [1]. Group 1: Company Developments - HAPO Pharmaceuticals has been involved in a significant project titled "Research on the Mechanism of Pancreatic Cancer and New Paradigms for Clinical Precision Diagnosis and Treatment," which has been officially approved as part of the National Science and Technology Innovation 2030 initiative [1]. - The company focuses on innovative antibody therapies in the fields of oncology and immune diseases, utilizing its proprietary fully human transgenic mouse platform, Harbour Mice® [1]. - HAPO has developed over 20 product pipelines, including bispecific antibodies, multi-specific antibodies, and antibody-drug conjugates (ADCs), and has established deep collaborations with major global pharmaceutical companies such as AstraZeneca, Pfizer, Bristol-Myers Squibb, Otsuka Pharmaceutical, AbbVie, and Moderna [1]. Group 2: Clinical Advancements - The company is advancing innovative therapies targeting CLDN18.2 and LIFR, which have entered clinical or application stages, thereby diversifying the treatment options for pancreatic cancer [1].
港股异动 | 和铂医药-B(02142)涨超3% 与长海医院联合申报的攻坚胰腺癌项目获国家科技创新重大专项立项